MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
1.361
-0.009
-0.69%
Opening 13:09 09/24 EDT
OPEN
1.390
PREV CLOSE
1.370
HIGH
1.390
LOW
1.345
VOLUME
33.74K
TURNOVER
--
52 WEEK HIGH
8.34
52 WEEK LOW
1.305
MARKET CAP
7.56M
P/E (TTM)
-0.4387
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACXP last week (0914-0918)?
Weekly Report · 3d ago
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
Barchart · 5d ago
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
Benzinga · 6d ago
Weekly Report: what happened at ACXP last week (0907-0911)?
Weekly Report · 09/14 10:22
Acurx Pharmaceuticals Files Prospectus For 1.5M Offering
Benzinga · 09/08 20:39
Acurx registers to sell 1.5M shares of common stock for holders
TipRanks · 09/08 20:30
Weekly Report: what happened at ACXP last week (0831-0904)?
Weekly Report · 09/07 10:16
Weekly Report: what happened at ACXP last week (0824-0828)?
Weekly Report · 08/31 10:23
More
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Webull offers Acurx Pharmaceuticals Inc stock information, including NASDAQ: ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.